{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T04:36:41Z","timestamp":1793939801488,"version":"4.8.0"},"reference-count":30,"publisher":"American Diabetes Association","issue":"9","license":[{"start":{"date-parts":[[2016,3,1]],"date-time":"2016-03-01T00:00:00Z","timestamp":1456790400000},"content-version":"vor","delay-in-days":264,"URL":"http:\/\/www.diabetesjournals.org\/site\/license"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["HHSN268201300046C"],"award-info":[{"award-number":["HHSN268201300046C"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["HHSN268201300047C"],"award-info":[{"award-number":["HHSN268201300047C"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["HHSN268201300048C"],"award-info":[{"award-number":["HHSN268201300048C"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["HHSN268201300049C"],"award-info":[{"award-number":["HHSN268201300049C"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["HHSN268201300050C"],"award-info":[{"award-number":["HHSN268201300050C"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01-HL117285"],"award-info":[{"award-number":["R01-HL117285"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["diabetesjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2015,9,1]]},"abstract":"<jats:sec><jats:title>OBJECTIVE<\/jats:title><jats:p>Previous studies on the association between hs-CRP and incident type 2 diabetes among African Americans have been inconclusive. We examined the association between hs-CRP and incident diabetes in a large African American cohort (Jackson Heart Study).<\/jats:p><\/jats:sec><jats:sec><jats:title>RESEARCH DESIGN AND METHODS<\/jats:title><jats:p>hs-CRP was measured in 3,340 participants. Incident diabetes was defined by fasting glucose \u2265126 mg\/dL, physician diagnosis, use of diabetes drugs, or A1C \u22656.5% (48 mmol\/mol) at follow-up. Cox regression was used to estimate hazard ratios (HRs) for incident diabetes, adjusting for age, sex, education, diabetes family history, alcohol, HDL, triglycerides, hypertension status, hypertension medications, physical activity, BMI, HOMA-insulin resistance (HOMAIR), and waist circumference.<\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS<\/jats:title><jats:p>Participants (63% women) were aged 53.3 \u00b1 12.5 years. During a median follow-up of 7.5 years, 17.4% developed diabetes (23.1\/1,000 person-years, 95% CI 21.3\u201325.1). After adjustment, the HR (hs-CRP third vs. first tertile) was 1.64 (95% CI 1.26\u20132.13). In separate models, further adjustment for BMI and waist circumference attenuated this association (HR 1.28 [95% CI 0.97\u20131.69] and 1.35 [95% CI 1.03\u20131.78, P &amp;lt; 0.05 for trend], respectively). Upon adding HOMAIR in the models, the association was no longer significant. In adjusted HOMAIR-stratified analysis, the hs-CRP\u2013diabetes association appeared stronger in participants with HOMAIR &amp;lt;3.0 compared with HOMAIR \u22653.0 (P &amp;lt; 0.0001 for interaction). The association was also stronger among nonobese participants, although not significant when adjusted for HOMAIR.<\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSIONS<\/jats:title><jats:p>Low-grade inflammation, as measured by hs-CRP level, may have an important role in the development of diabetes among African Americans with a lesser degree of insulin resistance.<\/jats:p><\/jats:sec>","DOI":"10.2337\/dc15-0221","type":"journal-article","created":{"date-parts":[[2015,6,12]],"date-time":"2015-06-12T03:17:10Z","timestamp":1434079030000},"page":"1694-1700","update-policy":"https:\/\/doi.org\/10.2337\/ada-journal-policies","source":"Crossref","is-referenced-by-count":76,"title":["High-Sensitivity C-Reactive Protein Is Associated With Incident Type 2 Diabetes Among African Americans: The Jackson Heart Study"],"prefix":"10.2337","volume":"38","author":[{"given":"Valery S.","family":"Effoe","sequence":"first","affiliation":[{"name":"Department of Epidemiology and Prevention, Wake Forest School of Medicine, Winston-Salem, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adolfo","family":"Correa","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Mississippi Medical Center, Jackson, MS"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiying","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Biostatistical Sciences, Wake Forest School of Medicine, Winston-Salem, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary E.","family":"Lacy","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, Brown University, Providence, RI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alain G.","family":"Bertoni","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Prevention, Wake Forest School of Medicine, Winston-Salem, NC"},{"name":"Maya Angelou Center for Health Equity, Wake Forest School of Medicine, Winston-Salem, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1167","published-online":{"date-parts":[[2015,6,11]]},"reference":[{"key":"2022031301082230000_B1","volume-title":"National Diabetes Statistics Report: Estimates of Diabetes and Its Burden in the United States, 2014","author":"Centers for Disease Control and Prevention","year":"2014"},{"key":"2022031301082230000_B2","doi-asserted-by":"crossref","first-page":"2384","DOI":"10.2337\/diabetes.50.10.2384","article-title":"The relation of markers of inflammation to the development of glucose disorders in the elderly: the Cardiovascular Health Study","volume":"50","author":"Barzilay","year":"2001","journal-title":"Diabetes"},{"key":"2022031301082230000_B3","doi-asserted-by":"crossref","first-page":"872","DOI":"10.2337\/db06-0922","article-title":"Genetic variation, C-reactive protein levels, and incidence of diabetes","volume":"56","author":"Dehghan","year":"2007","journal-title":"Diabetes"},{"key":"2022031301082230000_B4","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.2337\/diabetes.51.4.1131","article-title":"Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes: the insulin resistance atherosclerosis study","volume":"51","author":"Festa","year":"2002","journal-title":"Diabetes"},{"key":"2022031301082230000_B5","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.2337\/diabetes.51.5.1596","article-title":"C-reactive protein is an independent predictor of risk for the development of diabetes in the West of Scotland Coronary Prevention Study","volume":"51","author":"Freeman","year":"2002","journal-title":"Diabetes"},{"key":"2022031301082230000_B6","doi-asserted-by":"crossref","first-page":"2016","DOI":"10.2337\/diacare.25.11.2016","article-title":"Prospective study of C-reactive protein in relation to the development of diabetes and metabolic syndrome in the Mexico City Diabetes Study","volume":"25","author":"Han","year":"2002","journal-title":"Diabetes Care"},{"key":"2022031301082230000_B7","doi-asserted-by":"crossref","first-page":"693","DOI":"10.2337\/diabetes.53.3.693","article-title":"Inflammatory markers and risk of developing type 2 diabetes in women","volume":"53","author":"Hu","year":"2004","journal-title":"Diabetes"},{"key":"2022031301082230000_B8","doi-asserted-by":"crossref","first-page":"2754","DOI":"10.2337\/diacare.26.10.2754","article-title":"Elevated C-reactive protein is a risk factor for the development of type 2 diabetes in Japanese Americans","volume":"26","author":"Nakanishi","year":"2003","journal-title":"Diabetes Care"},{"key":"2022031301082230000_B9","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1001\/jama.286.3.327","article-title":"C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus","volume":"286","author":"Pradhan","year":"2001","journal-title":"JAMA"},{"key":"2022031301082230000_B10","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1001\/archinte.163.1.93","article-title":"C-reactive protein as a predictor for incident diabetes mellitus among middle-aged men: results from the MONICA Augsburg cohort study, 1984-1998","volume":"163","author":"Thorand","year":"2003","journal-title":"Arch Intern Med"},{"key":"2022031301082230000_B11","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.2337\/diabetes.52.7.1799","article-title":"Low-grade systemic inflammation and the development of type 2 diabetes: the atherosclerosis risk in communities study","volume":"52","author":"Duncan","year":"2003","journal-title":"Diabetes"},{"key":"2022031301082230000_B12","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.2337\/dc11-1957","article-title":"Racial differences in association of elevated interleukin-18 levels with type 2 diabetes: the Atherosclerosis Risk in Communities study","volume":"35","author":"Negi","year":"2012","journal-title":"Diabetes Care"},{"key":"2022031301082230000_B13","doi-asserted-by":"crossref","first-page":"804","DOI":"10.2337\/dc09-1679","article-title":"Inflammation and the incidence of type 2 diabetes: the Multi-Ethnic Study of Atherosclerosis (MESA)","volume":"33","author":"Bertoni","year":"2010","journal-title":"Diabetes Care"},{"key":"2022031301082230000_B14"},{"key":"2022031301082230000_B15"},{"key":"2022031301082230000_B16","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1097\/00000441-200409000-00001","article-title":"Laboratory, reading center, and coordinating center data management methods in the Jackson Heart Study","volume":"328","author":"Carpenter","year":"2004","journal-title":"Am J Med Sci"},{"key":"2022031301082230000_B17","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1007\/BF00280883","article-title":"Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man","volume":"28","author":"Matthews","year":"1985","journal-title":"Diabetologia"},{"key":"2022031301082230000_B18","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/j.amjcard.2008.05.049","article-title":"Epidemiology, heritability, and genetic linkage of C-reactive protein in African Americans (from the Jackson Heart Study)","volume":"102","author":"Fox","year":"2008","journal-title":"Am J Cardiol"},{"key":"2022031301082230000_B19","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1002\/sim.4780111204","article-title":"Effects of mid-point imputation on the analysis of doubly censored data","volume":"11","author":"Law","year":"1992","journal-title":"Stat Med"},{"key":"2022031301082230000_B20","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1002\/(SICI)1097-0258(19980130)17:2<219::AID-SIM735>3.0.CO;2-O","article-title":"Tutorial in biostatistics methods for interval-censored data","volume":"17","author":"Lindsey","year":"1998","journal-title":"Stat Med"},{"key":"2022031301082230000_B21","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1161\/01.STR.0000196941.58869.2d","article-title":"Midlife pulse pressure and incidence of dementia: the Honolulu-Asia Aging Study","volume":"37","author":"Freitag","year":"2006","journal-title":"Stroke"},{"key":"2022031301082230000_B22","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1093\/aje\/154.7.642","article-title":"Mortality with dementia: results from a French prospective community-based cohort","volume":"154","author":"Helmer","year":"2001","journal-title":"Am J Epidemiol"},{"key":"2022031301082230000_B23","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1056\/NEJMoa042378","article-title":"C-reactive protein levels and outcomes after statin therapy","volume":"352","author":"Ridker","year":"2005","journal-title":"N Engl J Med"},{"key":"2022031301082230000_B24","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1001\/jama.286.1.64","article-title":"Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation\/CRP evaluation (PRINCE): a randomized trial and cohort study","volume":"286","author":"Albert","year":"2001","journal-title":"JAMA"},{"key":"2022031301082230000_B25","doi-asserted-by":"crossref","first-page":"185","DOI":"10.5551\/jat.E543","article-title":"Immunohistochemical detection of oxidative stress biomarkers, dityrosine and N(epsilon)-(hexanoyl)lysine, and C-reactive protein in rabbit atherosclerotic lesions","volume":"15","author":"Fukuchi","year":"2008","journal-title":"J Atheroscler Thromb"},{"key":"2022031301082230000_B26","doi-asserted-by":"crossref","first-page":"3957","DOI":"10.4049\/jimmunol.163.7.3957","article-title":"Regulation of complement activation by C-reactive protein: targeting the complement inhibitory activity of factor H by an interaction with short consensus repeat domains 7 and 8-11","volume":"163","author":"Jarva","year":"1999","journal-title":"J Immunol"},{"key":"2022031301082230000_B27","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1161\/01.CIR.0000033116.22237.F9","article-title":"Demonstration that C-reactive protein decreases eNOS expression and bioactivity in human aortic endothelial cells","volume":"106","author":"Venugopal","year":"2002","journal-title":"Circulation"},{"key":"2022031301082230000_B28","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.1161\/01.CIR.102.18.2165","article-title":"Direct proinflammatory effect of C-reactive protein on human endothelial cells","volume":"102","author":"Pasceri","year":"2000","journal-title":"Circulation"},{"key":"2022031301082230000_B29","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1161\/01.CIR.102.9.1000","article-title":"Elevated C-reactive protein levels and impaired endothelial vasoreactivity in patients with coronary artery disease","volume":"102","author":"Fichtlscherer","year":"2000","journal-title":"Circulation"},{"key":"2022031301082230000_B30","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/j.bbrc.2006.05.170","article-title":"Activation of Toll-like receptor 4 is associated with insulin resistance in adipocytes","volume":"346","author":"Song","year":"2006","journal-title":"Biochem Biophys Res Commun"}],"container-title":["Diabetes Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/38\/9\/1694\/625474\/dc150221.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/38\/9\/1694\/625474\/dc150221.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,11]],"date-time":"2023-08-11T10:51:48Z","timestamp":1691751108000},"score":1,"resource":{"primary":{"URL":"https:\/\/diabetesjournals.org\/care\/article\/38\/9\/1694\/37247\/High-Sensitivity-C-Reactive-Protein-Is-Associated"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,6,11]]},"references-count":30,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2015,6,11]]},"published-print":{"date-parts":[[2015,9,1]]}},"URL":"https:\/\/doi.org\/10.2337\/dc15-0221","relation":{},"ISSN":["0149-5992","1935-5548"],"issn-type":[{"value":"0149-5992","type":"print"},{"value":"1935-5548","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,6,11]]}}}